152 related articles for article (PubMed ID: 30228214)
1. Reagent-saving immunohistochemistry for HER2 using non-contact alternating current electric field mixing.
Hoshino I; Imai K; Nanjo H; Nakamura R; Saito Y; Fujishima S; Saito H; Terata K; Wakita A; Sato Y; Motoyama S; Akagami Y; Minamiya Y
J Clin Pathol; 2019 Jan; 72(1):25-30. PubMed ID: 30228214
[TBL] [Abstract][Full Text] [Related]
2. Practical application of non-contact alternating current electric field mixing for reagent-saving in situ hybridisation of HER2.
Kurihara N; Imai K; Nanjo H; Nakamura R; Wakamatsu Y; Akagami K; Terata K; Wakita A; Sato Y; Motoyama S; Akagami Y; Minamiya Y
J Clin Pathol; 2019 Sep; 72(9):603-608. PubMed ID: 31129615
[TBL] [Abstract][Full Text] [Related]
3. Novel method for rapid in-situ hybridization of HER2 using non-contact alternating-current electric-field mixing.
Saito Y; Imai K; Nakamura R; Nanjo H; Terata K; Konno H; Akagami Y; Minamiya Y
Sci Rep; 2016 Jul; 6():30034. PubMed ID: 27443187
[TBL] [Abstract][Full Text] [Related]
4. Rapid HER2 cytologic fluorescence in situ hybridization for breast cancer using noncontact alternating current electric field mixing.
Watanabe SN; Imai K; Nanjo H; Wakamatsu Y; Kimura Y; Katayose Y; Kamata S; Terata K; Takahashi E; Ibonai A; Yamaguchi A; Konno H; Yatsuyanagi M; Kudo C; Takashima S; Akagami Y; Nakamura R; Sato Y; Motoyama S; Nomura K; Minamiya Y
Cancer Med; 2021 Jan; 10(2):586-594. PubMed ID: 33280268
[TBL] [Abstract][Full Text] [Related]
5. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
6. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
7. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
[TBL] [Abstract][Full Text] [Related]
8. HER2 immunohistochemical assessment with A0485 polyclonal antibody: is it time to refine the scoring criteria for the "2+" category?
Pennacchia I; Vecchio FM; Carbone A; Arena V
Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):31-5. PubMed ID: 25356940
[TBL] [Abstract][Full Text] [Related]
9. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.
Ainsworth R; Bartlett JM; Going JJ; Mallon EA; Forsyth A; Richmond J; Angerson W; Watters A; Dunne B
J Clin Pathol; 2005 Oct; 58(10):1086-90. PubMed ID: 16189156
[TBL] [Abstract][Full Text] [Related]
10. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
11. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
12. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
[TBL] [Abstract][Full Text] [Related]
13. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
14. Reading immunohistochemical slides on a computer monitor--a multisite performance study using 180 HER2-stained breast carcinomas.
Nassar A; Cohen C; Albitar M; Agersborg SS; Zhou W; Lynch KA; Heyman ER; Lange H; Siddiqui MT
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):212-7. PubMed ID: 21475038
[TBL] [Abstract][Full Text] [Related]
15. Validation of a fully automated HER2 staining kit in breast cancer.
Moelans CB; Kibbelaar RE; van den Heuvel MC; Castigliego D; de Weger RA; van Diest PJ
Cell Oncol; 2010; 32(1-2):149-55. PubMed ID: 20203372
[TBL] [Abstract][Full Text] [Related]
16. Computer-assisted assessment of the human epidermal growth factor receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls.
Hall BH; Ianosi-Irimie M; Javidian P; Chen W; Ganesan S; Foran DJ
BMC Med Imaging; 2008 Jun; 8():11. PubMed ID: 18534031
[TBL] [Abstract][Full Text] [Related]
17. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
Nwafor CC; Keshinro SO
Niger J Clin Pract; 2015; 18(4):553-8. PubMed ID: 25966732
[TBL] [Abstract][Full Text] [Related]
18. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies.
Lebeau A; Turzynski A; Braun S; Behrhof W; Fleige B; Schmitt WD; Grob TJ; Burkhardt L; Hölzel D; Jackisch C; Thomssen C; Müller V; Untch M
J Clin Oncol; 2010 Jul; 28(20):3264-70. PubMed ID: 20498397
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
[TBL] [Abstract][Full Text] [Related]
20. Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.
Prendeville S; Feeley L; Bennett MW; O'Connell F; Browne TJ
Am J Clin Pathol; 2016 Jan; 145(1):75-80. PubMed ID: 26712873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
